Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor open-label extension in sickle cell disease after GBT440-031
NL-OMON52948Phase 3Terminated
- Sponsor
- Global Blood Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of voxelotor in sickle cell disease (SCD) (2 arms), sponsored by Global Blood Therapeutics. Primary endpoints: Safety, Frequency of sickle cell disease-related complications and 1 more. Started Aug 2019; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON52948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52948.